Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07471048

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

Led by Sirt3 LLC · Updated on 2026-03-13

100

Participants Needed

1

Research Sites

182 weeks

Total Duration

On this page

Sponsors

S

Sirt3 LLC

Lead Sponsor

P

People Science, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate whether Viv, a consumer-grade dietary supplement derived from the Magnolia officinalis plant, has an effect on biomarkers of immune activity in adults with psoriasis. To address this question, this trial will compare Viv to a placebo (a look-alike substance that contains no drug). Participants will: * Take Viv or a placebo every day for 3 months. * Complete electronic questionnaires about their quality of life and psoriasis symptoms at the beginning of the study and again at 1 months and 3 months. * Be provided with at home blood collection kits, which they will use to collect blood at the beginning of the study and again at 1 months and 3 months. Researchers will analyze these blood samples to measure the levels of specific inflammatory proteins and evaluate how they change over the course of the study in the participants taking Viv compared to those taking placebo.

CONDITIONS

Official Title

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 18 years or older at time of consent
  • Diagnosis of stable psoriasis for at least 6 months confirmed by a dermatologist
  • Psoriasis-associated comorbidities including psoriatic arthritis allowed if not requiring systemic therapies
  • Able to read and understand English
  • Able to provide informed consent
  • Able to use a personal smartphone device and download the Chloe app
  • Able to receive product shipment within the United States
  • Willing and able to adhere to study protocol including blood sample collection and shipment
Not Eligible

You will not qualify if you...

  • No personal smartphone, no internet access, or unwilling to download Chloe app
  • Use of systemic non-biologic immunosuppressive agents within 8 weeks prior to randomization
  • Use of systemic biologic therapies within 6 months prior to randomization
  • Use of other systemic investigational drugs within 6 months prior to randomization
  • Currently pregnant, planning to become pregnant within 3 months, or breastfeeding
  • Medical conditions that could affect digestive symptom assessment or study outcomes
  • Significant illness or condition that may impact study participation or outcomes
  • Known allergy or hypersensitivity to magnolia, rice, or hypromellose
  • Unlikely to comply with trial or considered unsuitable by the Principal Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Decentralized Study Coordinating Center

Englewood, New Jersey, United States, 07631

Actively Recruiting

Loading map...

Research Team

A

Adeeb Rahman, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis | DecenTrialz